Table 2.
Demographic characteristics of study participants (n = 94)
| Variables | Median (range) |
|---|---|
| Age (months) | 78.1 (9.6–184.5) |
| Weight (kg) | 16.0 (5.7–36.4) |
| WAZ score | −2.1 (−4.9–2.2) |
| Height (cm) | 109.0 (64.0–156.8) |
| HAZ score | −2.6 (−6.6–3.8) |
| WHZ score | −0.4 (−4.6–10.0) |
| Body mass index (kg/m2) | 14.5 (8.8–20.2) |
| Body surface area (m2) | 0.7 (0.3–1.3) |
| Duration of ART (months) | 17 (1–54) |
| CD4, % | 12 (3–30) |
| Daily prescribed NVP dose (mg/m2/day), d4T:3TC:NVP | |
| 6:30:50 | 294.7 (178.6–476.2) |
| 10:40:70 | 280.0 (83.3–567.5)a |
| 30:150:200 | 353.1 (222.2–750.0) |
| Daily prescribed NVP dose (mg/m2/day) | |
| ≤3.0 years | 312.5 (178.6–567.5) |
| >3.0 years | 318.2 (83.3–750.0) |
| Daily prescribed NVP dose (mg/kg/day), d4T:3TC:NVP | |
| 6:30:50 | 13.6 (5.0–26.3) |
| 10:40:70 | 13.5 (3.3–25.9) |
| 30:150:200 | 14.2 (8.7–18.8) |
d4T, stavudine; NVP, nevirapine; 3TC, lamivudine.
aP < 0.05.